CD19-specific Chimeric Antigen Receptor [CS] class drugs

2 results

  • kymriah

    (Tisagenlecleucel)
    Novartis Pharmaceuticals Corporation
    Kymriah is a CD19-directed CAR-T cell therapy for patients up to 25 with refractory or relapsed B-cell precursor ALL; adults with relapsed/refractory large B-cell lymphoma after 2+ prior therapies; and adults with relapsed/refractory follicular lymphoma after 2+ prior therapies (accelerated approval).
    Medication Details
    Drug Interactions

  • yescarta

    (Axicabtagene Ciloleucel)
    Kite Pharma, Inc.
    Yescarta is a CAR-T cell therapy for adults with large B-cell lymphoma refractory to or relapsing after first-line chemoimmunotherapy, or after two or more prior therapies. Also indicated for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (accelerated approval).
    Medication Details
    Drug Interactions